Similarly, recombinant T-cell receptor ligand-1000 (RTL1000) is an HLA-DR-derived peptide that binds CD74.177 RTL1000 has been studied in a Phase 1 clinical trial for multiple sclerosis, demonstrating favorable safety and tolerability.178 These results may inform preclinical and clinical studies in primary CNS tumors. The gene discussed is CD74; the disease is multiple sclerosis.